Onkodok GmbH
- Address
- lock Available on a paid plan
Onkodok GmbH - Oncology and Hematology Research Center
Onkodok GmbH is a specialized clinical research center focused on advancing treatments across multiple cancer types and hematologic malignancies. The center demonstrates particular expertise in evaluating novel therapeutic combinations, personalized medicine approaches, and innovative immunotherapy strategies for patients with solid tumors and blood disorders.
- Lung Cancer: Conducting multiple phase III trials in NSCLC using next-generation immunotherapies, antibody-drug conjugates, and combination regimens
- Breast Cancer: Leading personalized therapy trials in HR+/HER2- and HER2+ early breast cancer, integrating dynamic biomarker assessment with targeted agents
- Gastrointestinal Malignancies: Investigating novel treatment combinations for advanced gastric and gastroesophageal junction adenocarcinomas with biomarker-driven approaches
- Hematologic Disorders: Evaluating treatment strategies in chronic lymphocytic leukemia and myeloproliferative neoplasms including polycythemia vera
The center's research portfolio emphasizes precision oncology and biomarker-driven patient selection, utilizing artificial intelligence and machine learning to predict treatment responses. Onkodok GmbH actively participates in international multicenter trials examining immune checkpoint inhibitors, CDK4/6 inhibitors, and antibody-drug conjugates, with a strong focus on improving outcomes through personalized therapeutic strategies. Their work spans early-stage neoadjuvant settings through advanced metastatic disease, addressing unmet needs in castration-resistant prostate cancer and other difficult-to-treat malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 47 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 44 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1AstraZeneca AB3active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB5trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Onkodok GmbH
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adjuvant Dynamic Marker-Adjusted Personalized Therapy: Ribociclib Plus Endocrine Therapy Versus Chemotherapy in HR+/HER2- Early Breast Cancer | WSG Westdeutsche Studiengruppe GmbH | Phase III | Not Recruiting | Jul 2019 | — |
IMP list
lock Showing 1 of 47 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Infliximab | 4 | Unknown | 2022-06-01 | 2025-01-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.